UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 106,091 Shares of AbbVie Inc. $ABBV

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 0.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,267,697 shares of the company's stock after purchasing an additional 106,091 shares during the quarter. AbbVie makes up about 0.7% of UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC's investment portfolio, making the stock its 21st largest position. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.81% of AbbVie worth $3,590,323,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Burk Holdings LLC purchased a new stake in AbbVie in the second quarter worth approximately $30,000. Litman Gregory Wealth Management LLC purchased a new position in shares of AbbVie during the fourth quarter worth approximately $28,000. Imprint Wealth LLC lifted its holdings in shares of AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company's stock worth $29,000 after acquiring an additional 45 shares during the last quarter. IFC & Insurance Marketing Inc. purchased a new stake in shares of AbbVie in the 4th quarter valued at $31,000. Finally, Marquette Asset Management LLC boosted its stake in shares of AbbVie by 52.2% in the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company's stock valued at $35,000 after purchasing an additional 48 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on ABBV shares. Piper Sandler lifted their target price on shares of AbbVie from $298.00 to $303.00 and gave the stock an "overweight" rating in a research report on Thursday, August 20th. Morgan Stanley restated an "overweight" rating and set a $296.00 price target on shares of AbbVie in a research report on Monday, August 3rd. BNP Paribas Exane raised their target price on shares of AbbVie from $218.00 to $247.00 and gave the stock a "neutral" rating in a report on Tuesday, August 11th. Sanford C. Bernstein restated a "market perform" rating on shares of AbbVie in a report on Tuesday, June 23rd. Finally, Bank of America raised their target price on shares of AbbVie from $234.00 to $276.00 and gave the stock a "buy" rating in a research report on Friday, July 10th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $275.95.

AbbVie Stock Down 0.1%

Shares of ABBV opened at $256.27 on Tuesday. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $267.47. The firm has a 50 day moving average of $254.71 and a 200 day moving average of $230.21. The company has a market capitalization of $452.78 billion, a P/E ratio of 72.39, a price-to-earnings-growth ratio of 1.16 and a beta of 0.29.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the prior year, the company posted $2.97 earnings per share. The company's quarterly revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, sell-side analysts expect that AbbVie Inc. will post 14.05 EPS for the current year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were paid a dividend of $1.73 per share. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.7%. AbbVie's payout ratio is currently 195.48%.

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the firm's stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president directly owned 74,430 shares of the company's stock, valued at approximately $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.06% of the company's stock.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.